Compare GIB & WST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GIB | WST |
|---|---|---|
| Founded | 1976 | 1923 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.0B | 18.5B |
| IPO Year | 1999 | 2004 |
| Metric | GIB | WST |
|---|---|---|
| Price | $76.93 | $278.23 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 7 |
| Target Price | $112.00 | ★ $320.86 |
| AVG Volume (30 Days) | 370.7K | ★ 745.1K |
| Earning Date | 04-29-2026 | 04-23-2026 |
| Dividend Yield | ★ 0.60% | 0.32% |
| EPS Growth | N/A | ★ 1.49 |
| EPS | N/A | ★ 6.79 |
| Revenue | N/A | ★ $2,886,900,000.00 |
| Revenue This Year | $8.33 | $6.76 |
| Revenue Next Year | $2.96 | $6.25 |
| P/E Ratio | ★ $13.59 | $40.32 |
| Revenue Growth | N/A | ★ 1.95 |
| 52 Week Low | $69.40 | $199.89 |
| 52 Week High | $110.07 | $322.34 |
| Indicator | GIB | WST |
|---|---|---|
| Relative Strength Index (RSI) | 61.66 | 71.02 |
| Support Level | $70.05 | $262.93 |
| Resistance Level | $93.65 | $280.54 |
| Average True Range (ATR) | 1.98 | 7.11 |
| MACD | 0.70 | 2.15 |
| Stochastic Oscillator | 89.18 | 94.41 |
CGI is a Canada-based IT-services provider with an embedded position in North America and Europe. The company is one of the major IT suppliers to different levels of government around the world. It offers a broad portfolio of services such as consulting, systems integration, application maintenance, and business process services to governments and the private sector. With offices in over 40 countries, CGI follows a balanced global delivery model with most consultants in client proximity.
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.